Oruka Therapeutics, Inc.
An open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
This open-label study with maintenance dosing to evaluate the long-term safety and efficacy of ORKA-002 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label maintenance period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last dose of ORKA-002.
Inclusion Criteria: 1. Signed informed consent by participants from previous trial choosing to transition into the Open-label study. 2. Participants who have successfully completed the preceding trial. 3. For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit. 4. For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception. Exclusion Criteria: 1. Participants who experienced any adverse events with ORKA-002 in the preceding trial that led…
ORKA-002 administered by subcutaneous (SC) injection